

Lia D'Ambrosio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5746088/publications.pdf>

Version: 2024-02-01

81
papers

6,029
citations

66234

42
h-index

74018

75
g-index

82
all docs

82
docs citations

82
times ranked

4577
citing authors

#	ARTICLE	IF	CITATIONS
1	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	0.8	9
2	Drug resistant TB – latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	1.5	37
3	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	1.5	18
4	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20210515.	0.4	6
5	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.4	10
6	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, 20210044.	0.4	15
7	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	1.0	18
8	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	3.1	86
9	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	0.6	59
10	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	1.5	5
11	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
12	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
13	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	3.1	273
14	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
15	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	1.5	126
16	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	1.3	8
17	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
18	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113

#	ARTICLE	IF	CITATIONS
19	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180420.	0.4	5
20	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
21	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, S457-S460.	0.6	9
22	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391.	3.1	81
23	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , 2019, 53, 1802184.	3.1	51
24	Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	1.5	21
25	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	3.1	50
26	Tuberculosis elimination: a dream or a reality? The case of Oman. <i>European Respiratory Journal</i> , 2018, 51, 1702027.	3.1	18
27	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. <i>European Respiratory Journal</i> , 2018, 51, 1702267.	3.1	10
28	Diagnostic performances of the Xpert MTB/RIF in Brazil. <i>Respiratory Medicine</i> , 2018, 134, 12-15.	1.3	13
29	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
30	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	3.1	59
31	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	3.0	76
32	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.4	23
33	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.4	23
34	Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015. <i>European Respiratory Journal</i> , 2017, 49, 1602309.	3.1	25
35	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	3.1	233
36	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , 2017, 49, 1700146.	3.1	59

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. <i>European Respiratory Journal</i> , 2017, 49, 1602-1615.	3.1	63
38	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. <i>International Journal of Infectious Diseases</i> , 2017, 56, 30-33.	1.5	22
39	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701-1712.	3.1	103
40	WHO Strategies for the Management of Drug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.4	5
41	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	1.5	82
42	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.4	6
43	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701-1714.	3.1	21
44	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	2.0	43
45	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.4	26
46	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	0.6	52
47	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. <i>Indian Journal of Medical Research</i> , 2017, 145, 261-263.	0.4	0
48	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. <i>Journal of Thoracic Disease</i> , 2016, 8, 2666-2671.	0.6	39
49	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. <i>Journal of Thoracic Disease</i> , 2016, 8, E474-E485.	0.6	45
50	Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels. <i>Journal of Thoracic Disease</i> , 2016, 8, 3307-3313.	0.6	3
51	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 374-385.	0.4	45
52	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	3.1	69
53	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	3.1	27
54	Faster for less: the new shorter regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	3.1	66

#	ARTICLE	IF	CITATIONS
55	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	3.1	75
56	WHO strategies for the programmatic management of drug-resistant tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 991-1002.	1.0	34
57	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2016, 387, 2486-2487.	6.3	47
58	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	3.1	71
59	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	3.1	84
60	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	3.1	34
61	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. <i>European Respiratory Journal</i> , 2016, 47, 686-688.	3.1	17
62	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	3.1	136
63	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1188.2-1190.	2.9	34
64	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	3.1	92
65	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	3.1	64
66	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. <i>European Respiratory Journal</i> , 2015, 45, 287-289.	3.1	19
67	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. <i>European Respiratory Journal</i> , 2015, 45, 289-291.	3.1	14
68	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	3.1	608
69	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 61, S102-S118.	2.9	74
70	The multidrug-resistant tuberculosis threat: old problems and new solutions. <i>Journal of Thoracic Disease</i> , 2015, 7, E354-60.	0.6	8
71	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. <i>Journal of Thoracic Disease</i> , 2015, 7, 1080-5.	0.6	8
72	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	3.1	96

#	ARTICLE	IF	CITATIONS
73	Tuberculosis elimination: dream or reality? The case of Cyprus. <i>European Respiratory Journal</i> , 2014, 44, 543-546.	3.1	46
74	The European Union standards for tuberculosis care: do they need an update?. <i>European Respiratory Journal</i> , 2014, 43, 933-942.	3.1	30
75	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	3.1	54
76	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	3.1	148
77	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. <i>European Respiratory Journal</i> , 2013, 42, 252-271.	3.1	211
78	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	3.1	226
79	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	3.1	346
80	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1â€™. <i>European Respiratory Journal</i> , 2013, 42, 288-290.	3.1	45
81	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2012, 40, 1430-1442.	3.1	346